Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting#Revolution #Medicines #Presents #Initial #Data #Zoldonrasib #RMC9805 #Study #Patients #KRAS #G12D #Mutant #NonSmall #Cell #Lung #Cancer #AACR #Annual #Meeting